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Br J Clin Pharmacol. 2019;1–4.Regulating drugs does not end when market access has been granted. Monitoring
drugs over the life cycle has become state of the art, inherent to evolving legislation
and societal need. Here, we explore how the drug label could move along in a changing
playing‐field and become a sustainable label for the future. A dialogue between acade-
mia, government, the pharmaceutical industry and patient/societal organizations was
organized by the Regulatory Science Network Netherlands. This is their view.
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Drug labels reflect the outcome of the assessment of drug dossiers,
as submitted by the applicant at the time of marketing authorization.
They are the result of elaborate dialogue between applicant and reg-
ulator. One could view the regulatory process as a funnel: from a
rich and vast amount of data emerges a clear and relatively succinct
mandate to produce, sell and use a pharmaceutical product, within
the framework of continuous monitoring and benefit–risk assess-
ment. The conditions for use are laid down in the drug label, in
Europe called the summary of product characteristics (SmPC). This
convergence of information that leads to the label also has a down-
side: the process of establishing the label is rather exclusive in terms
of the type and number of stakeholders involved. Moreover, scope
and clinical relevance remain limited, as well as the level of adaptive-
ness, or responsiveness to emerging knowledge, over time. To inves-
tigate these challenges and come up with suggestions to make the- - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution‐N
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armacology published by John Wi
's relevant? – Towards a sensible label' odrug label future‐proof, we organized an open dialogue within the
framework of the Regulatory Science Network Netherlands (RSNN;
Box 1), with experts covering a wide array of stakeholders, i.e. com-
panies (n = 52%), regulatory agencies (29%), universities (12.5%) and
patient/societal organizations (6%). The total number of participants
was 56. Three issues were raised.
First, we started exploring the stakeholder(s) responsible for con-
structing the SmPC: the applicant (usually a [bio]pharmaceutical com-
pany) and the regulator. From the perspective of the pharmaceutical
industry, the responsibility for transposing reliable, high quality data
into the label is with the applicant, i.e. the owner of the drug dossier,
and liability issues are strongly related to the assessment, and ulti-
mately granting of a marketing authorization. Marketing authoriza-
tion has an economic value to the company and leaves little space
for others to be involved. It is important to note that the label
reflects the outcome of the assessment procedure at the time of
marketing authorization, as performed by another stakeholder—the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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f the Regulatory Science Network Netherlands, RSNN, held on June 20th 2018 (https://www.
wileyonlinelibrary.com/journal/bcp 1
What is already known about this subject
• The drug label is part of the market authorization.
• The label is perceived as a contract between the marketing
authorization holder and regulatory authorities.
• Other parties are usually not involved in the process of
drafting the label
What this study adds
• A multistakeholder view on how the label could improve
over the drug life‐cycle.
• An innovative approach to enable effectiveness data
become part of the label.
• Defined conditions for shared responsibility that need
legal and regulatory consideration.
2 GISPEN‐DE WIED ET AL.regulator. It provides information about the safety, efficacy and
uncertainties of a medicinal product in the treatment of a specific
condition. Therefore, one could say that companies and regulators
share a mutual responsibility for the label, because it is the result
of a shared and interactive process. In reality, this means that the
label signifies the conditions for the competent authority, or even
the European Commission, to allow the company (or marketing
authorization holder, MAH) to place the product on the market. This
is essentially very restrictive in nature, and, as far as the law is con-
cerned, other stakeholders have a rather limited, or no, involvement.
Even though the wording of the label, and in particular the indica-
tion, is an extensive back and forth between the regulator and the
applicant, and a compromise at the time of market authorization,
regulatory authorities cannot add, for instance, an indication to a
label. Therefore, we consider the MAH in practice the principal
responsible stakeholder.BOX 1 | The Regulatory Science Network
Netherlands (RSNN) explained
WHAT IS THE RSNN
The RSNN, a network for experts from academia,
government, the pharmaceutical industry, patient
organizations and others involved in regulatory activities
related to drug development, aims to facilitate activities in
the field of regulatory science in the Netherlands by
stimulating dialogue and collaboration, and sharing
information and methods. The RSNN is aligned with other
European platforms active in the field. The RSNN
Newsletter informs participants and stakeholders of
activities and developments in the discipline (https://www.
lygature.org/regulatory‐science‐network‐netherlands‐rsnn).Second, we discussed the value of labels during the clinical applica-
tion of medicines. Apparently, this value is not always immediately
recognised by patients and consumers. They indicated a gap between
the information in the label and the patient's needs. Questions that
any patient may have are not always answered adequately by the
information in the label (or its derivative, the patient information leaf-
let). It does not provide, for instance, information about treatment
choice, or the use of a product in treatment regimens, as can be found
in professional guidelines. This raises the question of whether the label
is suited to act as a clinical guidance document. One could also see the
benefits of broadening the applicability of the label beyond detailing
the conditions for obtaining a marketing authorization. As explained,
the label is, legally, not intended as medical guideline, but may be used
by health professionals as a source of information, e.g. to update clin-
ical treatment guidelines. However, this does not mean that the label
cannot be the vessel to provide tailored information toward patients'
and health care professionals' needs. In current practice, there are
venues in different (regulatory) decision‐making bodies1 for patientsand consumers, together with the scientific community and society
at large, to express their views. Their rights and obligations as stake-
holder are, however, not well defined, and therefore the impact of
these stakeholders is not self‐evident.2
Third, labels are subject to continuous monitoring and adjustment
but are not sufficiently adaptive. In the current legal framework, safety
signals, originating from any source, may find their way, through the
Pharmacovigilance Risk Assessment Committee (in EU) into the label
because of specific pharmacovigilance legislation. During the work-
shop, this was perceived as a one‐sided and skewed adaptiveness
towards safety and limited because stakeholders other than the MAH,
e.g. regulatory authorities or the scientific community, cannot add any
information related to clinical effectiveness of a product. Evidence
generation is not only done by pharmaceutical companies, but also,
and increasingly so after marketing authorisation, by other organiza-
tions. Typical investigator driven research topics are the (appropriate)
use, the dose, or new indications (drug rediscovery) of medicines. For
this type of research, both interventional trials and observational stud-
ies in patient (outcome) registries or electronic health records are
used. The results of these studies hardly lead to adjustments of
the label, apart from the mentioned safety issues, as illustrated by
the 5‐fluorouracil (5FU) case and dose adjustment in the treatment
of colorectal and breast cancer3,4 (see Box 2). The label change was
based on safety considerations and a warning was added to the label
in section 4.4. Likewise, a dose adjustment in section 4.2 of the label
could have been decided on, provided both efficacy and safety issues
of a product are considered of equal importance. Either way, the 5FU
case demonstrates the need for a system that allows new information
to be incorporated in the label based on both risk and benefit data of a
drug. Most evidence generated from other sources than the MAH, as
in the 5FU case, does find its way extensively into professional guide-
lines and patient information, based on published papers and confer-
ence presentations. It is considered a lost opportunity, if these
findings are not used constructively for refining the label. If we accept
GISPEN‐DE WIED ET AL. 3the label as the core data source for efficacy and safety of a drug
throughout its life‐cycle, it is difficult to understand that it can only
cover part of the information available. From the perspective of a
pharmaceutical company, to take responsibility for the accuracy, qual-
ity and reliability of data generated by another stakeholder, outside of
their span of control, requires a data environment of full transparency
with regard to data quality, source, etc.5 Such an environment is cur-
rently not in place.BOX 2 | The example of the 5‐fluorouracil
(5FU) case and label adjustment
Dose adjustment based on an investigator driven study: the
5FU case
Fluoropyrimidines such as 5FU and capecitabine are widely
used anticancer drugs for the treatment of colorectal cancer
and breast cancer. The enzyme dihydropyrimidine
dehydrogenase (DPD) plays a key role in fluoropyrimidine
metabolism. DPD deficiency, which occurs in 3–5% of the
population, is associated with increased risk of severe/fatal
toxicity. Upfront screening and dose individualization can
improve patient safety. The Dutch Cancer Institute (NKI‐
AVL) took the initiative to conduct a prospective study to
individualise the dose of fluoropyrimidines based on
genotyping.2
The results showed that DPYD*2A carriers had 2‐fold
increased exposure to 5‐FU, meaning that a dose reduction
of 50% would be sufficient to achieve the desired clinical
effect. It was also shown that the genotype screening
strategy did not increase the total costs. Based on these
results and on the basis of a subsequent conducted meta‐
analysis, a practical dosing table for dose‐adaptation for
four different DPYD variants was developed.
The data were published in 2016, but did not result in a
change in the SmPC. As a follow‐up, the NKI‐AVL wrote a
letter to European Medicines Agency in January 2017.
Subsequently, DPD‐dependent dosing was discussed in the
Pharmacovigilance Risk Assessment Committee, with input
from NKI‐AVL and the marketing authorisation holder, and
in the PharmacogenomicsG Working Party, which resulted
in a positive advice to the Committee for Medicinal
Products for Human Use (CHMP). In the end, after
discussion with the marketing authorisation holder, the
proposed rewording of section 4.4 of the SmPCwas adopted.Altogether, one could argue that in current practice, the label
serves as target product profile for a marketing authorization and is
not fully suitable as information source for patients and prescribers
in daily practice. This position is rather monolithic and static, raising
the question of whether, and how the label could be made suitable
and sustainable as a future source of key drug information in a rapidlychanging environment where the emphasis is on timely marketing
authorization vs understanding the drug in clinical practice.2 | A SUSTAINABLE LABEL FOR THE
FUTURE
To make the label a state‐of‐the‐art document throughout the drug's
life cycle, we propose that the process to come to a sustainable label
for the future requires a model of shared stakeholders' responsibility.
The MAH, regulatory authorities, patients/consumers, health care pro-
fessionals and the scientific community all need to contribute.
As a first step, we recognise the label as an essential document for
granting the marketing authorization. The label is not only a crucial
document for the applicant; it is also the basis for liability questions,
and an important source for documents such as the patient informa-
tion leaflet. It should therefore be reliable and up‐to‐date with respect
to the safety and efficacy of the product itself, and not per se its appli-
cation and use in daily practice as part of the therapeutic arsenal as a
whole. This does not mean that the information at the time of market-
ing authorization cannot be optimized and more tailored towards user
and prescriber needs. We expect that this optimization will find its
way as a natural consequence of the patient/societal and scientific
community engagement in the drug development process before and
at the time of marketing authorization provided rights and obligations
of the new stakeholders are well defined; the label as core product
information document at the time of authorization. Once authorized,
other aspects regarding clinical use should be specified in professional
guidelines by medical professionals, e.g. by defining the product's
place in clinical treatment regimens. We conclude that reliable and
actual patient information should be based on professional guidelines
with respect to treatment (options) at one end, and on the label with
respect to product safety and efficacy information at the other end.
This means that the different stakeholders involved in the develop-
ment and maintenance of the label, and those involved in the develop-
ment and maintenance of professional guidelines, should interact with
each other and influence each other in an optimal way, inherent to the
model of shared stakeholder's responsibility that we propose. Prefera-
bly, early interaction between different stakeholders, as foreseen in
concepts, such as the priority medicines scheme PRIME, could be
explored. In doing so we must realise that daily clinical practice differs
significantly between countries and therefore, this process is not with-
out challenge, and asks for a willing attitude towards harmonization.
As part of our second step, we recognise that the label should fol-
low the drug life cycle and should thus be apt to provide information
acquired over time on efficacy and safety, based on a medicine's use
in daily practice. Building a system where new information from differ-
ent sources can fuel the label to become an up‐to‐date data source for
the actual use of drugs in daily practice is paramount. However,
criteria for the reviewing of these kind of data are needed. Any scien-
tific progress, new regulatory requirements and new (clinical effective-
ness) data that may come from additional phase 3 randomized
controlled trials, phase 4 randomized controlled trials (e.g. outcome tri-
als) and real‐world evidence (observational studies) can provide a new
4 GISPEN‐DE WIED ET AL.perspective on the efficacy and safety. The use of new types of data,
including nonpropriety data from e.g. investigator‐initiated pharmaco-
dynamics or drug–drug interaction studies, is useful to include in the
label because it evaluates the use, and the benefits and risks of med-
icines in more clinically diverse settings and patients, and under condi-
tions that reflect the use of treatments in actual clinical practice. There
is a need for legislation or mandate for European Medicines Agency
committees, to allow data from other stakeholders than the applicant,
i.e. the MAH, to be reviewed—according to usual standards—and find
its way into the drug label.
Thus, we propose a scenario where the end goal is one that the
label of the future should become a balanced rolling document, i.e. suit-
able to contain sensible information about the product's efficacy and
safety throughout its entire life‐cycle, from the time of marketing
authorization. By sensible, we mean that we accept that the informa-
tion in the label at the time of marketing authorization can also be
replaced by new information, if appropriate. We consider this a coura-
geous step forward in efficient regulation; it is easier to add informa-
tion to the label than to decide on redundancy.63 | CHALLENGES FOR A SHARED
STAKEHOLDER APPROACH
It is evident that the scenario described is not an easy way forward,
but following the proposed developments, it offers the opportunity
to focus discussions on the label in a stepwise approach: at the time
of market authorization and when the drug is on the market and used
in practice. For this approach to be successful, several challenges have
to be addressed:
• We need to (re)define each stakeholder in practical and legal con-
text within the current regulatory and legislative framework.
• There is a need for clarification of legal aspects within the current
framework, e.g. liability issues.
• We need to decide on the use of other data, i.e. not directly
obtained by the MAH, and define terms of data quality, transpar-
ency, data sources and access.
• We need a regulatory framework conducive to uptake of investiga-
tor initiated nontraditional data in the label.
Finally, to further this process of regulatory innovation, we advocate
two resolutions steps: (i) fuel discussions through the RSNN at Euro-
pean Medicines Agency level; and (ii) promote multi‐stakeholder regu-
latory research proposals in academia and beyond, e.g. participate in
Innovative Medicines Initiative, IMI projects.4 | CONCLUDING REMARKS
We asked ourselves questions such as: what should be the purpose of
the label of the future? What kind of information should be included (or
added) and what kind of information is redundant? Who should be the
owner of the label and who can be responsible for the development
and updating processes? We concluded on the need for a sharedstakeholder's responsibility and drafted a scenario that covers a 2‐step
approach, i.e. defining the label at the time of marketing authorization
and thereafter. We identified potential (legal) barriers that need to be
investigated, but, when further explored in the scientific regulatory
community, may pave the way for next steps, making the label
future‐proof.
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